Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after
heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant …

The cohort of long-term survivors of heart transplant is expanding, and the assessment of
these patients requires specific knowledge of the surgical techniques employed to implant …

CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …

Background—Cardiac allograft vasculopathy is a key prognostic determinant after heart
transplant. Detection and risk stratification of patients with cardiac allograft vasculopathy are …

The continued success of nuclear cardiology demands ongoing re-evaluation of imaging
practices to optimize patient care. The first element of this process is to accurately define …

Cardiac allograft vasculopathy (CAV) is an important cause of morbidity and mortality among
cardiac transplant recipients. CAV occurs in approximately 30% of patients by 5 years and …

Colvin‐Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future
direction. Clin Transplant 2011: 25: 175–184.© 2011 John Wiley & Sons A/S. Abstract …

The accurate noninvasive diagnosis and functional evaluation of coronary artery disease is
an important step in selecting the appropriate management strategy. Dobutamine stress …

Cardiac allograft vasculopathy (CAV) is an obliterative and diffuse form of vasculopathy
affecting almost 50% of patients after 10 years from heart transplant and represents the most …

Heart transplantation (HT) is an established life-saving treatment option for patients with end-
stage heart failure. Despite many advances in the field, the development of acute cellular …